196 related articles for article (PubMed ID: 32719125)
1. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
Guo E; Ishii Y; Mueller J; Srivatsan A; Gahman T; Putnam CD; Wang JYJ; Kolodner RD
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19415-19424. PubMed ID: 32719125
[TBL] [Abstract][Full Text] [Related]
2. PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.
Andronikou C; Burdova K; Dibitetto D; Lieftink C; Malzer E; Kuiken HJ; Gogola E; Ray Chaudhuri A; Beijersbergen RL; Hanzlikova H; Jonkers J; Rottenberg S
EMBO J; 2024 Mar; 43(6):1015-1042. PubMed ID: 38360994
[TBL] [Abstract][Full Text] [Related]
3. LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency.
Kulkarni A; Zhou J; Biyani N; Kathad U; Banerjee PP; Srivastava S; Prucsi Z; Solarczyk K; Bhatia K; Ewesuedo RB; Sharma P
Cancer Res Commun; 2024 May; 4(5):1199-1210. PubMed ID: 38630886
[TBL] [Abstract][Full Text] [Related]
4. Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.
Tseng WC; Chen CY; Chern CY; Wang CA; Lee WC; Chi YC; Cheng SF; Kuo YT; Chiu YC; Tseng ST; Lin PY; Liou SJ; Li YC; Chen CC
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922657
[TBL] [Abstract][Full Text] [Related]
5. Endogenous DNA 3' Blocks Are Vulnerabilities for BRCA1 and BRCA2 Deficiency and Are Reversed by the APE2 Nuclease.
Álvarez-Quilón A; Wojtaszek JL; Mathieu MC; Patel T; Appel CD; Hustedt N; Rossi SE; Wallace BD; Setiaputra D; Adam S; Ohashi Y; Melo H; Cho T; Gervais C; Muñoz IM; Grazzini E; Young JTF; Rouse J; Zinda M; Williams RS; Durocher D
Mol Cell; 2020 Jun; 78(6):1152-1165.e8. PubMed ID: 32516598
[TBL] [Abstract][Full Text] [Related]
6. FEN1 Inhibition as a Potential Novel Targeted Therapy against Breast Cancer and the Prognostic Relevance of FEN1.
Berfelde J; Hildebrand LS; Kuhlmann L; Fietkau R; Distel LV
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396787
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of synthetic lethality between BRCA1/2 and 53BP1 deficiencies and DNA polymerase theta targeting.
Ronson GE; Starowicz K; Anthony EJ; Piberger AL; Clarke LC; Garvin AJ; Beggs AD; Whalley CM; Edmonds MJ; Beesley JFJ; Morris JR
Nat Commun; 2023 Nov; 14(1):7834. PubMed ID: 38030626
[TBL] [Abstract][Full Text] [Related]
8. G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells.
McLuckie KI; Di Antonio M; Zecchini H; Xian J; Caldas C; Krippendorff BF; Tannahill D; Lowe C; Balasubramanian S
J Am Chem Soc; 2013 Jul; 135(26):9640-3. PubMed ID: 23782415
[TBL] [Abstract][Full Text] [Related]
9. Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins.
McGrail DJ; Li Y; Smith RS; Feng B; Dai H; Hu L; Dennehey B; Awasthi S; Mendillo ML; Sood AK; Mills GB; Lin SY; Yi SS; Sahni N
Cell Rep Med; 2023 Nov; 4(11):101255. PubMed ID: 37909041
[TBL] [Abstract][Full Text] [Related]
10. Cross-Species Complementation of Nonessential Yeast Genes Establishes Platforms for Testing Inhibitors of Human Proteins.
Hamza A; Driessen MRM; Tammpere E; O'Neil NJ; Hieter P
Genetics; 2020 Mar; 214(3):735-747. PubMed ID: 31937519
[TBL] [Abstract][Full Text] [Related]
11. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.
Ferretti S; Hamon J; de Kanter R; Scheufler C; Andraos-Rey R; Barbe S; Bechter E; Blank J; Bordas V; Dammassa E; Decker A; Di Nanni N; Dourdoigne M; Gavioli E; Hattenberger M; Heuser A; Hemmerlin C; Hinrichs J; Kerr G; Laborde L; Jaco I; Núñez EJ; Martus HJ; Quadt C; Reschke M; Romanet V; Schaeffer F; Schoepfer J; Schrapp M; Strang R; Voshol H; Wartmann M; Welly S; Zécri F; Hofmann F; Möbitz H; Cortés-Cros M
Nature; 2024 May; 629(8011):443-449. PubMed ID: 38658754
[TBL] [Abstract][Full Text] [Related]
12. Polyploid cells rewire DNA damage response networks to overcome replication stress-induced barriers for tumour progression.
Zheng L; Dai H; Zhou M; Li X; Liu C; Guo Z; Wu X; Wu J; Wang C; Zhong J; Huang Q; Garcia-Aguilar J; Pfeifer GP; Shen B
Nat Commun; 2012 May; 3():815. PubMed ID: 22569363
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair protein MLH1 suppresses replicative stress in BRCA2-deficient breast tumors.
Sengodan SK; Hu X; Peddibhotla V; Balamurugan K; Mitrophanov AY; McKennett L; Kharat SS; Sanawar R; Singh VK; Albaugh ME; Burkett SS; Zhao Y; Tran B; Malys T; Sterneck E; De S; Sharan SK
J Clin Invest; 2024 Jan; 134(7):. PubMed ID: 38271119
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic insights into FEN1-mediated drug sensitivity and risk signature in colon cancer: An integrative bioinformatics study.
Rao C; Tong J; Yang Y
Medicine (Baltimore); 2024 Mar; 103(13):e37517. PubMed ID: 38552056
[TBL] [Abstract][Full Text] [Related]
15. Recent Progress in DNA Damage Response-Targeting PROTAC Degraders.
Cheng B; Fei X; Ding Z; Peng X; Su Z; Pan W; Chen J
J Med Chem; 2024 May; 67(9):6906-6921. PubMed ID: 38663873
[TBL] [Abstract][Full Text] [Related]
16. The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistance.
Sanese P; De Marco K; Lepore Signorile M; La Rocca F; Forte G; Latrofa M; Fasano C; Disciglio V; Di Nicola E; Pantaleo A; Bianco G; Spilotro V; Ferroni C; Tubertini M; Labarile N; De Marinis L; Armentano R; Gigante G; Lantone V; Lantone G; Naldi M; Bartolini M; Varchi G; Del Rio A; Grossi V; Simone C
J Exp Clin Cancer Res; 2024 May; 43(1):151. PubMed ID: 38812026
[TBL] [Abstract][Full Text] [Related]
17. A cryptic targeting signal creates a mitochondrial FEN1 isoform with tailed R-Loop binding properties.
Kazak L; Reyes A; He J; Wood SR; Brea-Calvo G; Holen TT; Holt IJ
PLoS One; 2013; 8(5):e62340. PubMed ID: 23675412
[TBL] [Abstract][Full Text] [Related]
18. Replicative Instability Drives Cancer Progression.
Morris BB; Smith JP; Zhang Q; Jiang Z; Hampton OA; Churchman ML; Arnold SM; Owen DH; Gray JE; Dillon PM; Soliman HH; Stover DG; Colman H; Chakravarti A; Shain KH; Silva AS; Villano JL; Vogelbaum MA; Borges VF; Akerley WL; Gentzler RD; Hall RD; Matsen CB; Ulrich CM; Post AR; Nix DA; Singer EA; Larner JM; Stukenberg PT; Jones DR; Mayo MW
Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358918
[TBL] [Abstract][Full Text] [Related]
19. TATDN2 resolution of R-loops is required for survival of BRCA1-mutant cancer cells.
Jaiswal AS; Dutta A; Srinivasan G; Yuan Y; Zhou D; Shaheen M; Sadideen DT; Kirby A; Williamson EA; Gupta YK; Olsen SK; Xu M; Loranc E; Mukhopadhyay P; Pertsemlidis A; Bishop AJR; Sung P; Nickoloff JA; Hromas R
Nucleic Acids Res; 2023 Dec; 51(22):12224-12241. PubMed ID: 37953292
[TBL] [Abstract][Full Text] [Related]
20. Synthetic lethality between TP53 and ENDOD1.
Tang Z; Zeng M; Wang X; Guo C; Yue P; Zhang X; Lou H; Chen J; Mu D; Kong D; Carr AM; Liu C
Nat Commun; 2022 May; 13(1):2861. PubMed ID: 35606358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
